BI Asset Management Fondsmaeglerselskab A S Decreases Stock Holdings in Amgen, Inc. (NASDAQ:AMGN)
BI Asset Management Fondsmaeglerselskab A S lowered its stake in Amgen, Inc. (NASDAQ:AMGN) by 47.3% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 24,690 shares of the medical research company’s stock after selling 22,120 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in Amgen were worth $5,005,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors also recently modified their holdings of AMGN. Savior LLC purchased a new position in Amgen during the fourth quarter valued at $34,000. Harel Insurance Investments & Financial Services Ltd. increased its stake in shares of Amgen by 830.4% during the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,042 shares of the medical research company’s stock worth $251,000 after purchasing an additional 930 shares in the last quarter. Davis R M Inc. raised its position in shares of Amgen by 5.6% during the 4th quarter. Davis R M Inc. now owns 7,322 shares of the medical research company’s stock worth $1,765,000 after purchasing an additional 386 shares during the last quarter. Global Retirement Partners LLC raised its position in shares of Amgen by 4.6% during the 4th quarter. Global Retirement Partners LLC now owns 2,573 shares of the medical research company’s stock worth $620,000 after purchasing an additional 112 shares during the last quarter. Finally, J.W. Cole Advisors Inc. purchased a new position in Amgen in the 4th quarter valued at about $1,275,000. 76.41% of the stock is owned by institutional investors.
In related news, Director R Sanders Williams sold 425 shares of Amgen stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $237.31, for a total value of $100,856.75. Following the completion of the sale, the director now owns 5,834 shares in the company, valued at approximately $1,384,466.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ronald D. Sugar sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $233.35, for a total value of $233,350.00. Following the completion of the sale, the director now directly owns 15,636 shares in the company, valued at approximately $3,648,660.60. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 2,425 shares of company stock worth $563,477. Company insiders own 0.25% of the company’s stock.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Thursday, April 30th. The medical research company reported $4.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.70 by $0.47. Amgen had a net margin of 32.03% and a return on equity of 90.75%. The firm had revenue of $6.16 billion for the quarter, compared to analyst estimates of $6.01 billion. During the same period in the previous year, the firm earned $3.56 EPS. Amgen’s revenue was up 10.9% on a year-over-year basis. On average, sell-side analysts expect that Amgen, Inc. will post 15.58 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Monday, June 8th. Stockholders of record on Monday, May 18th will be paid a $1.60 dividend. This represents a $6.40 dividend on an annualized basis and a dividend yield of 2.83%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio (DPR) is 43.18%.
A number of equities analysts have commented on the company. Morgan Stanley increased their target price on Amgen from $267.00 to $280.00 and gave the company an “overweight” rating in a report on Friday, May 1st. Bank of America increased their price objective on Amgen from $250.00 to $265.00 and gave the company a “buy” rating in a research note on Friday, May 1st. BidaskClub raised shares of Amgen from a “sell” rating to a “hold” rating in a research note on Saturday, March 14th. Wolfe Research started coverage on shares of Amgen in a research report on Tuesday, March 31st. They issued a “market perform” rating and a $218.00 target price for the company. Finally, ValuEngine raised shares of Amgen from a “sell” rating to a “hold” rating in a research note on Tuesday, March 3rd. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating and seventeen have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $244.65.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Read More: Index Funds
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.